Literature DB >> 9177350

Neurotactin, a membrane-anchored chemokine upregulated in brain inflammation.

Y Pan1, C Lloyd, H Zhou, S Dolich, J Deeds, J A Gonzalo, J Vath, M Gosselin, J Ma, B Dussault, E Woolf, G Alperin, J Culpepper, J C Gutierrez-Ramos, D Gearing.   

Abstract

Chemokines are small secreted proteins that stimulate the directional migration of leukocytes and mediate inflammation. During screening of a murine choroid plexus complementary DNA library, we identified a new chemokine, designated neurotactin. Unlike other chemokines, neurotactin has a unique cysteine pattern, Cys-X-X-X-Cys, and is predicted to be a type 1 membrane protein. Full-length recombinant neurotactin is localized on the surface of transfected 293 cells. Recombinant neurotactin containing the chemokine domain is chemotactic for neutrophils both in vitro and in vivo. Neurotactin messenger RNA is predominantly expressed in normal murine brain and its protein expression in activated brain microglia is upregulated in mice with experimental autoimmune encephalomyelitis, as well as in mice treated with lipopolysaccharide. Distinct from all other chemokine genes, the neurotactin gene is localized to human chromosome 16q. Consequently we propose that neurotactin represents a new delta-chemokine family and that it may play a role in brain inflammation processes.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9177350     DOI: 10.1038/42491

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  156 in total

Review 1.  Role of chemokines in inflammation and immunoregulation.

Authors:  L Feng
Journal:  Immunol Res       Date:  2000       Impact factor: 2.829

2.  A novel nervous system beta subunit that downregulates human large conductance calcium-dependent potassium channels.

Authors:  T M Weiger; M H Holmqvist; I B Levitan; F T Clark; S Sprague; W J Huang; P Ge; C Wang; D Lawson; M E Jurman; M A Glucksmann; I Silos-Santiago; P S DiStefano; R Curtis
Journal:  J Neurosci       Date:  2000-05-15       Impact factor: 6.167

3.  Fractalkine (CX3CL1) as an amplification circuit of polarized Th1 responses.

Authors:  P Fraticelli; M Sironi; G Bianchi; D D'Ambrosio; C Albanesi; A Stoppacciaro; M Chieppa; P Allavena; L Ruco; G Girolomoni; F Sinigaglia; A Vecchi; A Mantovani
Journal:  J Clin Invest       Date:  2001-05       Impact factor: 14.808

4.  Neutralization of macrophage inflammatory protein 2 (MIP-2) and MIP-1alpha attenuates neutrophil recruitment in the central nervous system during experimental bacterial meningitis.

Authors:  A Diab; H Abdalla; H L Li; F D Shi; J Zhu; B Höjberg; L Lindquist; B Wretlind; M Bakhiet; H Link
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

5.  The fractalkine receptor CX3CR1 is a key mediator of atherogenesis.

Authors:  Myron I Cybulsky; Robert A Hegele
Journal:  J Clin Invest       Date:  2003-04       Impact factor: 14.808

Review 6.  Chemokines and glial cells: a complex network in the central nervous system.

Authors:  Elena Ambrosini; Francesca Aloisi
Journal:  Neurochem Res       Date:  2004-05       Impact factor: 3.996

7.  Fractalkine receptor CX(3)CR1 is expressed in epithelial ovarian carcinoma cells and required for motility and adhesion to peritoneal mesothelial cells.

Authors:  Mijung Kim; Lisa Rooper; Jia Xie; Andre A Kajdacsy-Balla; Maria V Barbolina
Journal:  Mol Cancer Res       Date:  2011-11-07       Impact factor: 5.852

8.  Neuron-Microglia Dialogue and Hippocampal Neurogenesis in the Aged Brain.

Authors:  Carmelina Gemma; Adam D Bachstetter; Paula C Bickford
Journal:  Aging Dis       Date:  2010-12-01       Impact factor: 6.745

9.  Cloning and functional characterization of the human fractalkine receptor promoter regions.

Authors:  Alexandre Garin; Philippe Pellet; Philippe Deterre; Patrice Debré; Christophe Combadière
Journal:  Biochem J       Date:  2002-12-15       Impact factor: 3.857

10.  Next-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials.

Authors:  Markus Mandler; Elvira Valera; Edward Rockenstein; Harald Weninger; Christina Patrick; Anthony Adame; Radmila Santic; Stefanie Meindl; Benjamin Vigl; Oskar Smrzka; Achim Schneeberger; Frank Mattner; Eliezer Masliah
Journal:  Acta Neuropathol       Date:  2014-02-14       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.